{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:35:36Z","timestamp":1761744936640,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.dsx.2021.102264","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:49:42Z","timestamp":1630450182000},"page":"102264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2)"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-8864","authenticated-orcid":false,"given":"Banshi","family":"Saboo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dsx.2021.102264_bib1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s13300-018-0416-2","article-title":"Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: interim report from post-marketing surveillance","volume":"9","author":"Haneda","year":"2018","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.dsx.2021.102264_bib2","series-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes research and clinical practice","first-page":"107843","volume":"vol. 157","author":"Saeedi","year":"2019"},{"key":"10.1016\/j.dsx.2021.102264_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2147\/DMSO.S202458","article-title":"QT\/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the \u201cthorough QT\/QTc\u201d study (Q-SET study)","volume":"12","author":"Erande","year":"2019","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"issue":"19","key":"10.1016\/j.dsx.2021.102264_bib4","first-page":"1199","article-title":"Prospective observational study on the analysis of utilisation pattern, safety and effectiveness of teneligliptin in type 2 diabetic patients with cardiovascular disease","volume":"7","author":"George","year":"2018","journal-title":"World J Pharmaceut Res"},{"key":"10.1016\/j.dsx.2021.102264_bib5","first-page":"2450","article-title":"Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure","volume":"8","author":"Kankanala","year":"2016","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.dsx.2021.102264_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2021.102264_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/DMSO.S35682","article-title":"Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"6","author":"Kishimoto","year":"2013","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"key":"10.1016\/j.dsx.2021.102264_bib8","article-title":"Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dsx.2021.102264_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.29","article-title":"Pharmacokinetics of teneligliptin in subjects with renal impairment","volume":"2","author":"Halabi","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.dsx.2021.102264_bib10","first-page":"41","article-title":"Evaluation of safety and effectiveness of teneligliptin when shifted from other gliptins uncontrolled with type 2 diabetes mellitus","volume":"6","author":"Gupta","year":"2019","journal-title":"Int J Sci Stud"},{"issue":"1","key":"10.1016\/j.dsx.2021.102264_bib11","article-title":"Evaluation of the safety and efficacy of teneligliptin at a higher dose in Indian type 2 diabetes patients: a retrospective analysis","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.dsx.2021.102264_bib12","first-page":"88","article-title":"Effect of teneligliptin on QT interval in type II diabetes mellitus patients: a retrospective evaluation","volume":"6","author":"Sengupta","year":"2019","journal-title":"Int J Sci Stud"},{"issue":"10","key":"10.1016\/j.dsx.2021.102264_bib13","first-page":"14-19","article-title":"A\u00a0ProspectIve, OpeN-label, randomized study comparing EffIcacy and safety of teneligliptin VErsus sitagliptin in Indian patients with inadequately controlled type 2 diabetes mellitus: INSITES study","volume":"67","author":"Mohan","year":"2019","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.dsx.2021.102264_bib14","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.18203\/2320-6012.ijrms20181296","article-title":"Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes","volume":"6","author":"Chatterjee","year":"2018","journal-title":"Int J Res Med Sci"},{"key":"10.1016\/j.dsx.2021.102264_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/ijem.IJEM_97_16","article-title":"Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: a randomized, double-blind study","volume":"22","author":"Agarwal","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2021.102264_bib16","first-page":"287","article-title":"Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes","volume":"6","author":"Kutoh","year":"2014","journal-title":"J\u00a0Clin Med Res"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:18Z","timestamp":1761729618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121002848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1871402121002848"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102264","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Diabetes India.","name":"copyright","label":"Copyright"}],"article-number":"102264"}}